Overview

A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects

Status:
Completed
Trial end date:
2006-06-02
Target enrollment:
Participant gender:
Summary
The study was designed to assess the steady-state pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release tablet formulation (25 mg) in healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine